Here is Eli Lilly’s competitive edge in GLP-1 obesity drugs and Abbott’s secondary play

Health, Fitness & Food

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.)

Products You May Like

Articles You May Like

How Much Does a Planet Fitness Membership Cost? Here’s What You Get For the Price
‘Wealth can be pretty isolating’: Problems that rich people face, according to therapists
Walgreens to offer its own cheaper version of opioid overdose reversal drug naloxone
Roche says weight loss drug shows promising results in early trial
Danaher’s rally shows how sticking with a troubled stock of a good company can pay off

Leave a Reply

Your email address will not be published. Required fields are marked *